Assembly Biosciences (ASMB) Coverage Initiated by Analysts at B. Riley

Analysts at B. Riley began coverage on shares of Assembly Biosciences (NASDAQ:ASMB) in a report issued on Friday, January 5th, MarketBeat.com reports. The firm set a “neutral” rating and a $35.00 price target on the biopharmaceutical company’s stock. B. Riley’s price target would indicate a potential downside of 28.82% from the company’s previous close.

ASMB has been the topic of a number of other research reports. Chardan Capital reissued a “buy” rating on shares of Assembly Biosciences in a research report on Sunday, September 17th. Zacks Investment Research raised shares of Assembly Biosciences from a “hold” rating to a “buy” rating and set a $37.00 price objective on the stock in a research report on Wednesday, November 15th. ValuEngine downgraded shares of Assembly Biosciences from a “hold” rating to a “sell” rating in a research report on Thursday, December 7th. BidaskClub cut shares of Assembly Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 6th. Finally, Jefferies Group started coverage on shares of Assembly Biosciences in a research note on Wednesday, November 8th. They issued a “buy” rating and a $50.00 target price for the company. One analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company’s stock. Assembly Biosciences currently has an average rating of “Hold” and an average price target of $39.25.

Assembly Biosciences (NASDAQ:ASMB) traded up $0.57 during mid-day trading on Friday, reaching $49.17. 152,080 shares of the company’s stock traded hands, compared to its average volume of 129,186. The company has a market capitalization of $865.48, a price-to-earnings ratio of -16.56 and a beta of 0.90. Assembly Biosciences has a fifty-two week low of $18.48 and a fifty-two week high of $52.37.

Assembly Biosciences (NASDAQ:ASMB) last announced its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.17. analysts anticipate that Assembly Biosciences will post -3.22 EPS for the current fiscal year.

In other Assembly Biosciences news, Director William R. Ringo sold 1,000 shares of Assembly Biosciences stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $49.37, for a total transaction of $49,370.00. Following the completion of the sale, the director now directly owns 20,465 shares in the company, valued at approximately $1,010,357.05. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last 90 days, insiders have sold 3,000 shares of company stock valued at $123,960. Company insiders own 19.60% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Nationwide Fund Advisors purchased a new stake in Assembly Biosciences in the 2nd quarter worth $161,000. Parametric Portfolio Associates LLC increased its holdings in Assembly Biosciences by 13.6% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 10,078 shares of the biopharmaceutical company’s stock worth $208,000 after acquiring an additional 1,203 shares in the last quarter. Legal & General Group Plc purchased a new stake in shares of Assembly Biosciences during the second quarter worth $212,000. Wells Fargo & Company MN purchased a new stake in shares of Assembly Biosciences during the second quarter worth $213,000. Finally, State of Wisconsin Investment Board purchased a new stake in shares of Assembly Biosciences during the second quarter worth $227,000. Hedge funds and other institutional investors own 61.44% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Assembly Biosciences (ASMB) Coverage Initiated by Analysts at B. Riley” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/28/assembly-biosciences-asmb-receives-new-coverage-from-analysts-at-b-riley.html.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply